Target Discovery and Validation Reviews and Protocols, Volumes 1 and 2 review the most progressive and current methods for drug target discovery and validation. These volumes explore how recent improvement in understanding the molecular mechanisms of human pathology is impacting drug target discovery in the laboratory and in real therapeutics, specifically for cancers and autoimmune disorders. Volume 1 focuses on novel and innovative techniques, and presents the most up-to-date protocols available for maximizing the likelihood of achieving target-selective inhibition in vivo while minimizing side effects. The profound impact of genomics, proteomics and bioinformatics on target discovery is explored, and specific attention is given to the role of transgenic and knockout animals in functional genomics and target validation. Cancer researchers will find tremendous value in the molecular classification of breast cancers and the review of protocols for tumor antigens and cancer vaccines. The methods and protocols collected here, all reviewed by leading scientists and clinicians, present the practical details necessary for translating the enormous discovery potential of the genome into real therapeutic products.
Volume 2 collects all the practical details required for efficient translation of discovered targets into real pharmaceutical drugs. Specific targets in cancers and autoimmunity are described and the potential of using siRNAs, antisense oligonucleotides and RNA aptamers in patients is reviewed. This volume explores the tremendous impact of the application of genotyping and gene expression profiling on the future of healthcare, and presents cutting-edge protocols to aid in bringing agents against specific targets closer to application in the clinic. Collectively, these volumes provide a thorough review of the most cutting-edge methods available for each step in drug target identification, validation, and clinical application. For researchers, an understanding of available methods aids in the creation of innovative experiments in the laboratory, and the successful translation of target discovery to real therapeutics.
From the reviews: "...provide a thorough review of the most cutting-edge methods available for each step in drug target identification, validation, and clinical applications." -Anticancer Research "Review current methods for drug target discovery and validation. ! the chapters are generally well written and clear, and provide extensive references to the current literature. Overall ! provide useful overviews that would provide entry into this field. Novice and more experienced researchers ! would find useful information ! ." (Jonathan B. Chaires, ChemMedChem, Issue 3, 2008)
Part II: Emerging molecular targets and treatment options 1. Druggable signaling proteins Mouldy Sioud and Marianne leirdal 2. DNA methylation and histone modifications in patients with cancer: Potential prognostic and therapeutic targets Michael Herranz and Manel Esteller 3. Wnt signaling as therapeutic target for cancer Andreas Herbst and Frank Thomas Kolligs 4. The NG2/HMP proteoglycan as a cancer therapeutic target Martha Chekenya and Heike Immervoll 5. Heterotrimeric G proteins and disease A yvind Melien 6. High Mobility Group Box1 isoforms as potential therapeutic targets in sepsis William Parrish and Luis Ulloa 7. Antisense oligonucleotides: Target validation and development of systemically-delivered therapeutic nanoparticles Chuanbo Zhang, Jin Pei, Deepak Kumar, Isamu Sakabe, Howard E. Boudreau, Prafulla C. Gokhale, and Usha N. Kasid 8. Therapeutic applications of RNA-based aptamers de Franciscis Vittorio 9. Guidelines for the selection of effective siRNA sequences for functional genomics and therapeutic applications Kumiko Ui-Tei, Yuki Naito, and Kaoru Saigo 10. Suppression of apoptosis in the liver by systematic and local delivery of siRNA Lars Zender and Stefan Kubicka 11. Inhibition of tumour growth by intratumoral delivery of siRNAs Seyedhossein Aharinejad, Mouldy Sioud, Trevor Lucas, and Dietmar Abraham 12. Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small interfering RNAs Nadia Zaffaroni, Marzia Pennati, and Marco Folini 13. Collagen-induced arthritis in mice: A major role for TNFa Richard O. Williams 14. Novel opportunities for therapeutic targeting in systemic autoimmune diseases Meryem Ouarzane and Moncef Zouali 15. Regulatory RNAs: Future perspectives in diagnosis, prognosis and individualized therapy Provost Patrick 16. Therapeutic options and individualized medicine Mouldy Sioud A yvind Melien NB. Chapters 8 and 15, which I am now editing, will be send on Monday.
There are currently no reviews for this product. Be the first to review this product!